Novo Nordisk A/S
$ 47.26
2.81%
07 Aug - close price
- Market Cap 203,221,893,000 USD
- Current Price $ 47.26
- High / Low $ 47.50 / 46.73
- Stock P/E 11.05
- Book Value 7.01
- EPS 4.16
- Next Earning Report -
- Dividend Per Share $11.70
- Dividend Yield 4.05 %
- Next Dividend Date -
- ROA 0.19 %
- ROE 0.60 %
- 52 Week High 61.89
- 52 Week Low 34.58
About
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Analyst Target Price
$47.20
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-03 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-05 | 2024-11-06 | 2024-08-07 | 2024-05-02 | 2024-01-31 | 2023-11-02 |
| Reported EPS | 0.96 | 6.63 | 6.04 | 1.02 | 5.96 | 6.53 | 6.34 | 6.12 | 0.66 | 0.83 | 0.71 | 0.73 |
| Estimated EPS | 0.82 | 6.96 | 5.9 | 0.77 | 6 | 6.07 | 5.97 | 5.92 | 0.7366 | 0.77 | 0.66 | 0.69 |
| Surprise | 0.14 | -0.33 | 0.14 | 0.25 | -0.04 | 0.46 | 0.37 | 0.2 | -0.0766 | 0.06 | 0.05 | 0.04 |
| Surprise Percentage | 17.0732% | -4.7414% | 2.3729% | 32.4675% | -0.6667% | 7.5783% | 6.1977% | 3.3784% | -10.3991% | 7.7922% | 7.5758% | 5.7971% |
Previous Dividend Records
| Aug 2026 | Apr 2026 | Aug 2025 | Apr 2025 | Aug 2024 | Apr 2024 | Aug 2023 | Apr 2023 | Aug 2022 | Apr 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-08-25 | 2026-04-08 | 2025-08-26 | 2025-04-08 | 2024-08-26 | 2024-04-02 | 2023-08-29 | 2023-04-04 | 2022-08-23 | 2022-04-05 |
| Amount | $0.578578 | $1.217376 | $0.584816 | $1.099206 | $0.5169016 | $0.92985 | $0.8835613 | $1.1887415 | $0.5835507 | $1.0360282 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NVO
2026-08-07 22:39:55
Eli Lilly plans to file for FDA approval for its next-generation weight-loss drug, retatrutide, in the first quarter of 2027. Clinical trials show retatrutide has superior efficacy compared to existing treatments like Novo Nordisk's Wegovy, potentially expanding Eli Lilly's leadership in the weight-loss market. The company's financial performance continues to be strong, driven by its current weight-loss medications and a diversified pipeline in other therapeutic areas.
2026-08-07 13:11:32
Karsten Munk Knudsen, CFO of Novo Nordisk, described his nine years on the leadership team as a "roller coaster," navigating periods of low growth, hyper-growth fueled by demand for their obesity drugs, and subsequent growth slowdown. He emphasized the pressure and responsibility of steering the high-profile pharma company. Despite mixed data for their new drug CagriSema, Knudsen remains optimistic about its prospects as a competitive diabetes product.
2026-08-07 00:11:32
Pharmaceutical giant Novo Nordisk has selected Omnicom as its U.S. media agency of record following a review. The company spends approximately $600 million annually on media and previously worked with WPP's Wavemaker. This new partnership aims to scale consumer-focused strategies and connect with patients, especially those with chronic conditions like obesity and diabetes, through emerging channels.
2026-08-06 22:52:00
A U.S. federal judge has dismissed an antitrust lawsuit against Eli Lilly and Novo Nordisk filed by compounding pharmacy Strive Specialties. Strive had accused the pharmaceutical giants of illegally blocking access to customized versions of their GLP-1 weight-loss drugs through exclusive deals with telehealth providers. The judge ruled that Strive failed to plausibly allege a product market and did not adequately show how it was harmed, stating that antitrust laws protect competition, not individual competitors.
2026-08-06 19:11:32
Novo Nordisk is a Danish pharmaceutical giant founded in 1923, primarily known for its diabetes and obesity treatments, including the blockbuster drugs Ozempic and Wegovy. The company's core business revolves around insulin and GLP-1 receptor agonists like semaglutide, with a significant portion of its revenue coming from its diabetes and obesity care segment. Novo Nordisk is controlled by the Novo Nordisk Foundation, which influences its long-term strategy, and its shares are traded on the Nasdaq Copenhagen exchange and NYSE.
2026-08-06 13:11:14
Novo Nordisk has won a lawsuit in the Netherlands against Ceban Ziekenhuisfarmacie, a compounding pharmacy that was distributing a nasal spray formulation of semaglutide called Semanova. The court ruled that Ceban infringed on Novo Nordisk's supplementary protection certificate (SPC) for semaglutide, which protects Ozempic, Rybelsus, and Wegovy. This decision reinforces intellectual property rights in the pharmaceutical industry and highlights that compounded medicines are not exempt from patent laws, especially when bulk manufactured or marketed at scale.
